400 related articles for article (PubMed ID: 17172607)
1. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.
Langer-Gould A; Popat RA; Huang SM; Cobb K; Fontoura P; Gould MK; Nelson LM
Arch Neurol; 2006 Dec; 63(12):1686-91. PubMed ID: 17172607
[TBL] [Abstract][Full Text] [Related]
2. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis.
Binquet C; Quantin C; Le Teuff G; Pagliano JF; Abrahamowicz M; Moreau T
Neuroepidemiology; 2006; 27(1):45-54. PubMed ID: 16825794
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
Achiron A; Barak Y; Rotstein Z
Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
[TBL] [Abstract][Full Text] [Related]
5. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
6. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
[TBL] [Abstract][Full Text] [Related]
7. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
8. Disability and prognosis of relapsing remitting multiple sclerosis, is it different in Iraqi patients?
Hasan ZN
Neurosciences (Riyadh); 2011 Jul; 16(3):233-6. PubMed ID: 21677613
[TBL] [Abstract][Full Text] [Related]
9. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of disability in relapsing remitting multiple sclerosis.
Briggs FBS; Thompson NR; Conway DS
Mult Scler Relat Disord; 2019 May; 30():9-16. PubMed ID: 30711764
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
12. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
13. Defining reliable disability outcomes in multiple sclerosis.
Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
[TBL] [Abstract][Full Text] [Related]
14. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
[TBL] [Abstract][Full Text] [Related]
15. Self-reported levels of education and disability progression in multiple sclerosis.
D'hooghe MB; Haentjens P; Van Remoortel A; De Keyser J; Nagels G
Acta Neurol Scand; 2016 Dec; 134(6):414-419. PubMed ID: 27761897
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis.
Baumstarck K; Pelletier J; Butzkueven H; Fernández O; Flachenecker P; Idiman E; Stecchi S; Boucekine M; Auquier P;
Eur J Neurol; 2013 Jun; 20(6):907-14, e78-9. PubMed ID: 23347258
[TBL] [Abstract][Full Text] [Related]
17. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
[TBL] [Abstract][Full Text] [Related]
18. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of multiple sclerosis with early onset.
Ghezzi A; Pozzilli C; Liguori M; Marrosu MG; Milani N; Milanese C; Simone I; Zaffaroni M
Mult Scler; 2002 Apr; 8(2):115-8. PubMed ID: 11990867
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
Ramsaransing GS; De Keyser J
Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
